Previous Section | Back to Table of Contents | Lords Hansard Home Page |
www.dh.gov.uk/en/Freedomofinformation/Freedomofinformationpublicationschemefeedback/FOIreleases/DH_076693
They can be found in the file marked "Vol.79 June 1978-February 1996". The department is committed to releasing all relevant documents held from the period 1970 to 1985. Over 5,500 documents have been placed on the department's website since 2006.
Asked by Lord Morris of Aberavon
To ask Her Majesty's Government what assessment they have made of how many (a) adults, and (b) children, in the United Kingdom have type 1 diabetes. [HL2884]
To ask Her Majesty's Government what assessment they have made of the number of people in England who are diagnosed with type 1 diabetes each year compared with (a) Scotland, and (b) Wales. [HL2885]
The Parliamentary Under-Secretary of State, Department of Health (Baroness Thornton): We have not undertaken a formal assessment of the number of adults and children diagnosed with type 1 diabetes. Data from the quality and outcomes framework (QOF) show that that number of people with diabetes has increased annually. However, it is not possible from the QOF data to differentiate between people with type 1 or type 2 diabetes.
QOF-Number of patients with a recorded diagnosis of diabetes | ||||
2004-05 | 2005-06 | 2006-07 | 2007-08 | 2008-09 |
The diabetes register only includes patients aged 17 years and over, as the care of children with diabetes is generally under the control of specialists. Data from Growing Up with Diabetes: Children and Young People with Diabetes in England reported that in February 2009 there were 22,947 children and young people with diabetes. Of this number, 20,488 were classified as having type 1 diabetes.
Without exact data on the number of people with type 1 diabetes, we are not able to make direct comparisons with other countries.
Asked by Lord Morris of Aberavon
To ask Her Majesty's Government what assessment they have made of the cost to the National Health Service of treating type 1 diabetes and its effects. [HL2886]
To ask Her Majesty's Government what is their estimate of the lifetime cost of medical treatment for a patient with type 1 diabetes. [HL2887]
Baroness Thornton: We have not undertaken either a formal assessment of the costs of treating people with type 1 diabetes, or estimated the lifetime costs of treating a person with type 1 diabetes.
Diabetes is a complex lifelong condition that can affect every part of the body, and there are a number of associated complications with the condition; this makes it difficult to calculate the exact cost to the National Health Service.
Asked by Lord Morris of Aberavon
To ask Her Majesty's Government how many people with type 1 diabetes who use insulin pump therapy are offered access to a dose adjustment for normal eating (DAFNE) course or an equivalent course. [HL2931]
Baroness Thornton: There are no data held centrally about how many people with type 1 diabetes who use an insulin pump have attended a dose adjustment for normal eating (DAFNE) course or such equivalent.
Patient education is an essential part of diabetes care and many diabetes services commission or run courses to educate patients about type 1 diabetes.
The DAFNE course is designed to educate patients (usually over the age of 17) with type 1 diabetes to help them manage their multi-injection therapy, the most common treatment for type 1 diabetes. The DAFNE course is not designed specifically for people with insulin pumps. However, centres that provide DAFNE would advise that all potential pump users attend a DAFNE course before commencing pump therapy.
To ask Her Majesty's Government how many working days have been lost due to diabetes and its effects in each of the past five years. [HL3020]
Baroness Thornton: There are no data collected centrally about how many working days have been lost due to diabetes and its effects in each of the past five years.
To ask Her Majesty's Government what estimate they have made of the cost of diabetes and its effects. [HL3021]
Baroness Thornton: Diabetes is a complex lifelong condition that can affect every part of the body. There are a number of associated complications with the condition which makes it difficult to calculate the exact total cost to the National Health Service.
The department's programme budget figures indicate £1.26 billion of departmental gross expenditure in England in 2008-09 was spent on diabetes. This figure does not include spending on prevention or on general medical services or primary medical services.
£000s | |||
Diabetes expenditure | DH gross expenditure | Diabetes as a proportion of gross expenditure | |
In England in 2008, according to the NHS Business Services Authority, about £595 million for diabetes-related items was spent on prescriptions dispensed in the community; ie by community pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by prescribing doctors for items personally administered. Also included are prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England.
Drug group | NIC(£000s) |
NIC is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees or prescription charges income).
Further expenditure will have taken place throughout the NHS system that is not possible to identify. Diabetes UK estimates spending in the United Kingdom is approximately £9 billion across the NHS.
To ask Her Majesty's Government whether they have undertaken a cost-benefit analysis of the effects of the qualifying age range of 40 to 74 for the NHS
6 Apr 2010 : Column WA406
Baroness Thornton: The National Health Service Health Check programme (formerly vascular checks) is a universal and systematic programme for everyone between the ages of 40 and 74 that will assess an individual's risk of heart disease, stroke, kidney disease and diabetes and will support people to reduce or manage that risk through individually tailored advice. The programme was developed on the basis of advice from the National Screening Committee. It advised that, on current evidence, there was not a case for whole population screening for diabetes. However, there was a good case for targeted screening for diabetes in the wider context of cardiovascular risk assessment.
The department undertook modelling on a vascular risk assessment and management programme, which included diabetes, to establish whether such an approach would be cost and clinically effective as well as identifying the optimal starting age. Both the technical consultation on the modelling and the impact assessment are available in the House of Lords Library. Three different starting ages for the programme (40, 45 and 50) were modelled. The age range of 40 to 74 for everyone was found to be both clinically and cost effective.
In taking the decision about the age range with which to launch the programme, the department took further advice from the National Screening Committee and leading United Kingdom diabetologists. Their view was that, given the current state of knowledge, age 40 represented a good starting point for combined diabetes, cardio-vascular and kidney disease risk assessment. The content and age parameters of the programme will be kept under review.
We understand that some primary care trusts may be inviting people into the programme who are under 40 years of age, for example, in areas that have significant South Asian communities who are generally at higher risk of vascular disease including diabetes. However, this scenario was not tested through the modelling, and so we have no evidence of its clinical or cost effectiveness.
Asked by Lord Alton of Liverpool
To ask Her Majesty's Government whether insulin-dependent diabetes has been successfully treated in any species by nuclear transfer; and, if so, how. [HL3060]
Baroness Thornton: The Government are not aware of insulin-dependent (or type 1) diabetes having been successfully treated in any species by nuclear transfer. This Government will continue to support all types of stem cell research to maximise the possibility of developing new treatments for unmet medical needs, such as type 1 diabetes.
To ask Her Majesty's Government what assessment they have made of the treatment of diabetes with the drug Avandia. [HL3079]
Baroness Thornton: The Government have made no such assessment. The independent National Institute for Health and Clinical Excellence (NICE) has made a number of recommendations about the use of thiazolidinediones, which include rosiglitazone (Avandia), in its clinical guideline on newer agents for type 2 diabetes published in May 2009. Further information can be found on NICE's website at http://guidance. nice.org.uk/CG87
Asked by Baroness Finlay of Llandaff
To ask Her Majesty's Government what discussions they have had with interested parties, such as the British Medical Association and employers, to resolve gaps in junior doctor rotas. [HL2893]
The Parliamentary Under-Secretary of State, Department of Health (Baroness Thornton): It is for strategic health authorities (SHAs) and National Health Service trusts to ensure that they resolve any gaps in their service delivery to ensure patient safety. It has been agreed that future monitoring will be managed at SHA and trust level.
Asked by Baroness Finlay of Llandaff
To ask Her Majesty's Government what action they are taking regarding junior doctor training within the scope of the European working time directive. [HL2894]
Baroness Thornton: There is a review under way, which is looking at the impact of the European working time directive on junior doctors' training in the reduced hours environment. This is independently headed by Professor Sir John Temple, on behalf of Medical Education England.
Asked by Baroness Finlay of Llandaff
To ask Her Majesty's Government what research they have undertaken to ascertain the effect of gaps in junior and middle-grade doctor rotas on patient safety. [HL2895]
Baroness Thornton: Quality assurance of middle and junior rota gaps began in March 2009 and continued until July 2009.
Trusts were asked to report via the strategic health authorities (SHAs) on potential service risks around the August 2009 medical change over dates.
The trusts were asked to report on the impact of the European working time directive, as well as any shortfall in specialty recruitment and shortages of medical locums. A risk rating for each trust was provided along with mitigating actions.
Daily situation reporting arrangements were set up to cover the first two weeks of August 2009.
From August 2009, only those rotas experiencing compliance difficulties were monitored.
The return in January 2010 reported a continual improvement in the compliance position and a steady reduction of the number of rotas reporting difficulties.
SHAs and trusts will manage any future monitoring.
Asked by Baroness Finlay of Llandaff
To ask Her Majesty's Government what assessment they have made of the opportunities for use of simulation in junior doctor training. [HL2896]
Baroness Thornton: The use of simulation-based training is already well established for junior doctors. We encourage the appropriate use of modern education techniques including simulation-based clinical training for all clinical staff to improve training and patient outcomes.
Asked by Baroness Finlay of Llandaff
To ask Her Majesty's Government what discussions they have had on alterations to junior doctor training following the implementation of the European working time directive in August 2009. [HL2897]
Baroness Thornton: Professor Sir John Temple is leading an independent review on the impact of the European working time directive on junior doctors' training in the reduced hour environment, on behalf of Medical Education England.
This comprehensive review is taking account of evidence from a wide range of stakeholders including junior doctors.
To ask Her Majesty's Government further to the Written Answer by Baroness Thornton on 17 March (WA 189), whether they will place in the Library of the House the exchange of letters between the United Kingdom and Ireland on the payment of €100 million healthcare costs for 2003-06, and on the settlement for 2007-09. [HL2993]
The Parliamentary Under-Secretary of State, Department of Health (Baroness Thornton): Correspondence between the department and the Irish Government on this matter has been provided on a confidential basis. Therefore, to publish it would be a breach of confidence and would be prejudicial to international relations with the Irish Government. For these reasons, the exchange of letters will not be placed in the Library.
Next Section | Back to Table of Contents | Lords Hansard Home Page |